> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Haemonetics Lifts Revenue Outlook To 8% To 11% Growth, Cuts Margin Expansion Target
- URL: https://www.bullished.co/haemonetics-lifts-revenue-outlook-to-8-to-11-growth-cuts-margin-expansion-target-891e2e3f/
- Published: 2026-11-05T11:26:06.000Z
- Updated: 2026-11-05T11:26:06.000Z
- Description: The plasma and blood-technology maker raised its sales forecast but now sees 0 to 50 basis points of margin expansion, down from 50 to 100.
- Author: Matteo Parrino
- Tags: SEC Filings, HAE, Industry: Healthcare

[Haemonetics](https://www.bullished.co/tag/hae/), which makes devices, disposables and software for collecting and managing blood and plasma, raised its fiscal 2027 reported revenue growth forecast to [8% to 11%](https://www.sec.gov/Archives/edgar/data/0000313143/000031314326000150/ex991-fy27q2earningsrelease.htm?ref=bullished.co) from 5% to 8%, while cutting its outlook for adjusted operating margin expansion. The company announced the changes Thursday with second-quarter results.

## Sales up, margin outlook down

Adjusted operating margin is now expected to expand 0 to 50 basis points (up to half a percentage point) from last year, versus 50 to 100 basis points in the earlier guidance. Organic revenue growth, which excludes currency and exited liquid-solution products, is now guided at 6% to 9%, up from 4% to 7%.

The company now expects high-single-digit growth in Apheresis, its plasma and blood collection unit, against low- to mid-single-digit before. MedSurg, its hospital unit, is still guided to mid-single-digit growth. Free cash flow conversion is expected above 80%, up from about 80%.

The second-quarter margin figure helps explain the trim: adjusted operating margin was 26.3%, down 40 basis points from a year earlier, as adjusted operating expenses rose 15.2% on personnel costs and freight.

## Plasma drives a 9.3% revenue gain

Second-quarter revenue was [$357.8 million](https://www.wusa9.com/article/syndication/associatedpress/haemonetics-fiscal-q2-earnings-snapshot/616-8e364a2b-a34c-4564-926a-8dcfd277b30c?ref=bullished.co), up 9.3%, or 10.0% organically. Apheresis rose 12.6% to $204.8 million, with plasma up 16.5% to $162.6 million. MedSurg climbed 5.1% to $153.0 million.

Net income rose to [$46.3 million](https://www.wusa9.com/article/syndication/associatedpress/haemonetics-fiscal-q2-earnings-snapshot/616-8e364a2b-a34c-4564-926a-8dcfd277b30c?ref=bullished.co), or $1.00 per diluted share, from $38.7 million, or $0.81\. Adjusted earnings were $1.35 per share, up 6.3%.

Gross margin was 61.7%, up from 59.5%. The company credited refunded tariffs, a shift to higher-margin products and the absence of an inventory step-up charge. The effective tax rate rose to 26.3% from 24.6%.

## Cash and a CSL expansion

Operating cash flow was $128.1 million and free cash flow $103.8 million in the quarter. Cash stood at $260.7 million at quarter's end, and long-term debt fell to $1.11 billion from $1.22 billion at the end of fiscal 2026 after the company repaid revolver borrowings.

CEO Chris Simon pointed to the "Expansion of our CSL relationship" and innovation milestones in both businesses as strengthening its competitive position. Management hosted a call at 8:00 a.m. ET Thursday to discuss the results and outlook.

Hospital products made up 44.1% of fiscal 2026 revenue and plasma 39.3%, so the plasma strength in this quarter's results carries real weight.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — HAEMONETICS CORP (HAE)](https://www.sec.gov/Archives/edgar/data/0000313143/000031314326000150/hae-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ex991-fy27q2earningsrelease.htm — HAEMONETICS CORP 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000313143/000031314326000150/ex991-fy27q2earningsrelease.htm?ref=bullished.co) — SEC EDGAR
- [Haemonetics sees double-digit growth](https://theedgemalaysia.com/article/haemonetics-sees-double-digit-growth?type=Markets&ref=bullished.co) — The Edge Malaysia
- [Haemonetics: Fiscal Q2 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/haemonetics-fiscal-q2-earnings-snapshot/616-8e364a2b-a34c-4564-926a-8dcfd277b30c?ref=bullished.co) — Associated Press

### More on Haemonetics

- [CSL Expects Haemonetics Devices In All Its U.S. Plasma Centers By End Of 2027, 8-K Says](https://www.bullished.co/csl-expects-haemonetics-devices-in-all-its-u-s-plasma-centers-by-end-of-2027-8-k-says-cff5f575/)

[All Haemonetics (HAE) coverage →](https://www.bullished.co/tag/hae/)